Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Morphotek

- PMLiVE

Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s

Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients

- PMLiVE

Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline

The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

- PMLiVE

Medicus Pharma completes patient enrolment for basal cell carcinoma trial

Interim results have shown over 60% clinical clearance in patients treated with SkinJect

- PMLiVE

Researchers at University of Geneva develop test platform for cancer treatments

The new platform could speed up testing while reducing the need for animal models

- PMLiVE

Eisai submits new drug application for subcutaneous Leqembi in Japan

LEQEMBI is a treatment for early Alzheimer’s disease

- PMLiVE

Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

- PMLiVE

Merck and Blackstone agree on funding for cancer protein antibody

The funding will support late-stage clinical development of the investigational antibody-drug conjugate

- PMLiVE

Corcept Therapeutics reports positive phase 3 results in ovarian cancer treatment

The company also plans to expand its phase 2 BELLA study to include three new study arms

- PMLiVE

Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

- PMLiVE

Eli Lilly’s Inluriyo approved by FDA for breast cancer

The oral drug can be used to treat advanced or metastatic breast cancer

- PMLiVE

Lilly and Circle Pharma agree to collaborate on new oral macrocycle therapies

The agreement is part of the Lilly Catalyze360 model, designed to empower early-stage biotechs

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links